| Literature DB >> 20049653 |
Gunn Signe Jakobsen1, Dag Hofsø, Jo Røislien, Rune Sandbu, Jøran Hjelmesaeth.
Abstract
BACKGROUND: Bariatric surgery particularly benefits patients with obesity-related comorbidities such as type 2 diabetes and obstructive sleep apnea. We aimed to examine whether the variables that influence treatment choice differ between morbidly obese patients undergoing bariatric surgery and those opting for conservative treatments.Entities:
Mesh:
Year: 2010 PMID: 20049653 PMCID: PMC2910888 DOI: 10.1007/s11695-009-0053-y
Source DB: PubMed Journal: Obes Surg ISSN: 0960-8923 Impact factor: 4.129
Fig. 1Flowchart of patients and treatment choice
Demographic and clinical characteristics
| SG ( | CTG ( |
| |
|---|---|---|---|
| Female | 180 (72%) | 173 (68%) | 0.304 |
| Age (years) | 41 (11) | 44 (13) | 0.002 |
| BMI (kg/m2) | 46.5 (6.2) | 43.2 (5.5) | <0.001 |
| Body weight (kg) | 136 (23.2; range 90–226) | 127 (20.5; range 82–200) | <0.001 |
| Waist circumference (cm) | 136 (15) | 131 (14) | <0.001 |
| Hip circumference (cm) | 137 (12) | 133 (15) | <0.001 |
| Waist-to-hip ratio | 1.00 (0.10) | 1.00 (0.10) | 0.696 |
| Maximum weight (kg) | 143 (24) | 134 (23) | <0.001 |
| Max weight, age (years) | 38 (11) | 41 (14) | 0.057 |
| Previous bariatric surgery | 11 (4%) | 5 (2%) | 0.135 |
Data are means (SD) for continuous variables and n (%) for categorical variables
Fig. 2Age. Distribution of the patients in the surgery group (SG) and the conservative treatment group (CTG) according to age The chi-square test was used for statistical analysis
Fig. 3Age at onset of obesity. Distribution of the patients in the surgery group (SG) and the conservative treatment group (CTG) according to age at onset of obesity. The chi-square test was used for statistical analysis
Fig. 4BMI. Proportion of patients within each BMI category who underwent surgery (SG) or received conservative treatment (CTG). The chi-square test was used for statistical analysis
Comorbidities and drug therapy according to treatment choice
| SG ( | CTG ( |
| |
|---|---|---|---|
| Type 2 diabetes | 57 (23%) | 58 (23%) | 1.000 |
| Antidiabetic drugs | 44 (18%) | 36 (14%) | 0.332 |
| No. of drugs | |||
| 1 | 25 (10%) | 16 (6%) | 0.388 |
| ≥2 | 19 (8%) | 21 (8%) | |
| Hypertension | 127 (51%) | 136 (53%) | 0.698 |
| Antihypertensive drugs | 79 (32%) | 89 (35%) | 0.529 |
| No of drugs1 | |||
| 1 | 34 (14%) | 41 (16%) | |
| 2 | 25 (10%) | 27 (11%) | 0.877 |
| ≥3 | 20 (8%) | 21 (8%) | |
| Obstructive sleep apnoea | 36 (15%) | 45 (18%) | 0.404 |
| Asthma | 55 (22%) | 52 (20%) | 0.704 |
| COPD | 9 (4%) | 9 (4%) | 1.000 |
| Asthma and/or COPD | 62 (25%) | 58 (23%) | 0.626 |
| Asthma and COPD (drugs) | 53 (21%) | 45 (18%) | 0.347 |
| Joint pain | 155 (62%) | 150 (59%) | 0.454 |
| Pain killers | 70 (28%) | 57 (22%) | 0.158 |
| Hyperlipidemia | 180 (72%) | 168 (66%) | 0.128 |
| Statins | 27 (11%) | 32 (13%) | 0.659 |
| Anxiety/depression | 88 (35%) | 102 (40%) | 0.314 |
| Coronary heart disease | 10 (4%) | 16 (6%) | 0.350 |
| Current smoking | 74 (30%) | 66 (25%) | 0.484 |
Data are n (%)
COPD chronic obstructive pulmonary disease
Odds for having surgery according to BMI, age, gender, onset of obesity, and weight-related comorbidities
| Explanatory variables | Model 1 |
| Model 2 |
| Model 3 |
| Model 4 |
| Model 5 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||||
| BMI | ||||||||||
| <40.0 kg/m2 | 1 | 1 | 1 | 1 | 1 | |||||
| 40.0–49.9 kg/m2 | 3.05 (1.90–4.90) | <0.001 | 3.15 (1.95–5.10) | <0.001 | 3.07 (1.89–4.99) | <0.001 | 3.02 (1.85–4.91) | <0.001 | 3.12 (1.91–5.07) | <0.001 |
| ≥50.0 kg/m2 | 6.07 (3.25–11.32) | <0.001 | 6.33 (3.36–11.94) | <0.001 | 5.88 (3.08–11.25) | <0.001 | 5.73 (3.00–10.99) | <0.001 | 5.86 (3.01–11.22) | <0.001 |
| Age | 0.98 (0.96–0.99) | 0.003 | 0.98 (0.97–1.00) | 0.064 | 0.98 (0.96–1.00) | 0.022 | 0.98 (0.96–1.00) | 0.022 | ||
| Gender | 0.75 (0.50–1.12) | 0.152 | 0.71 (0.47–1.10) | 0.095 | 0.68 (0.45–1.03) | 0.068 | 0.69 (0.46–1.05) | 0.082 | ||
| Age at onset of obesity | ||||||||||
| >20 years | 1 | 0.135 | 1 | 0.125 | 1 | 0.148 | ||||
| <12 years | 1.59 (1.00–2.52) | 0.051 | 1.61 (1.01–2.57) | 0.044 | 1.59 (0.99–2.49) | 0.057 | ||||
| 12–20 years | 1.36 (0.83–2.23) | 0.223 | 1.35 (0.82–2.21) | 0.242 | 1.36 (0.83–2.05) | 0.221 | ||||
| Weight-related comorbidities | 1.16 (0.99–1.40) | 0.107 | ||||||||
| Type 2 diabetes | 1.28 (0.80–2.05) | 0.303 | ||||||||
Model 1 BMI as explanatory variable in the logistic regression model, model 2 explanatory variables as in model 1 plus age and gender, model 3 explanatory variables as in model 2 plus age at onset of obesity, model 4 explanatory variables as in model 3 plus sum of weight-related comorbidities as a continuous variable (type 2 diabetes, yes = 1, no = 0; hypertension, yes = 1, no = 0; obstructive sleep apnea, yes = 1, no = 0; dyslipidemia, yes = 1, no = 0; and joint pain, yes=1, no = 0), model 5 explanatory variables as in model 3 plus type 2 diabetes